155 related articles for article (PubMed ID: 37934724)
21. Successful treatment with lorlatinib in a patient with meningeal carcinomatosis of ALK-positive non-small cell lung cancer resistant to alectinib and brigatinib: A case report.
Nakashima K; Demura Y; Kurokawa K; Takeda T; Jikuya N; Oi M; Tada T; Akai M; Ishizuka T
Medicine (Baltimore); 2021 Oct; 100(39):e27385. PubMed ID: 34596160
[TBL] [Abstract][Full Text] [Related]
22. Targeting EML4-ALK gene fusion variant 3 in thyroid cancer.
Aydemirli MD; van Eendenburg JDH; van Wezel T; Oosting J; Corver WE; Kapiteijn E; Morreau H
Endocr Relat Cancer; 2021 May; 28(6):377-389. PubMed ID: 33878728
[TBL] [Abstract][Full Text] [Related]
23. Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience.
Rupp M; Fanton-Aita F; Snow S; Wheatley-Price P; Melosky B; Juergens RA; Chu Q; Blais N; Banerji S; Ng R; Khoudigian S; Sharma A; On PV; Liu G
Curr Oncol; 2023 Jul; 30(7):6559-6574. PubMed ID: 37504341
[TBL] [Abstract][Full Text] [Related]
24. An update on lorlatinib: a novel first line treatment for
Riudavets M; Planchard D
Expert Opin Pharmacother; 2023 Feb; 24(3):291-299. PubMed ID: 36542835
[TBL] [Abstract][Full Text] [Related]
25. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
[TBL] [Abstract][Full Text] [Related]
26. Lorlatinib as a treatment for ALK-positive lung cancer.
Baba K; Goto Y
Future Oncol; 2022 Aug; 18(24):2745-2766. PubMed ID: 35787143
[TBL] [Abstract][Full Text] [Related]
27. miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
Lai Y; Kacal M; Kanony M; Stukan I; Jatta K; Kis L; Norberg E; Vakifahmetoglu-Norberg H; Lewensohn R; Hydbring P; Ekman S
Biochem Biophys Res Commun; 2019 Apr; 511(2):260-265. PubMed ID: 30791979
[TBL] [Abstract][Full Text] [Related]
28. A case of one lung adenocarcinoma patient harboring a novel FAM179A-ALK (F1, A19) rearrangement responding to lorlatinib treatment.
Yan J; Zhou X; Pan D
Lung Cancer; 2020 Sep; 147():26-29. PubMed ID: 32652371
[TBL] [Abstract][Full Text] [Related]
29. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.
Kimura H; Nakajima T; Takeuchi K; Soda M; Mano H; Iizasa T; Matsui Y; Yoshino M; Shingyoji M; Itakura M; Itami M; Ikebe D; Yokoi S; Kageyama H; Ohira M; Nakagawara A
Lung Cancer; 2012 Jan; 75(1):66-72. PubMed ID: 21757253
[TBL] [Abstract][Full Text] [Related]
30. Excellent response of lung adenocarcinoma harboring a rare SLC8A1 downstream intergenic region ALK fusion to ceritinib treatment: A case report.
Fang L; Ding G; Wang M; Ye Y; Yan X; Ding P; Wang J; Zhang Y
Medicine (Baltimore); 2022 Aug; 101(34):e30255. PubMed ID: 36042596
[TBL] [Abstract][Full Text] [Related]
31. Clinical Management of Adverse Events Associated with Lorlatinib.
Bauer TM; Felip E; Solomon BJ; Thurm H; Peltz G; Chioda MD; Shaw AT
Oncologist; 2019 Aug; 24(8):1103-1110. PubMed ID: 30890623
[TBL] [Abstract][Full Text] [Related]
32. First-line crizotinib therapy is effective for a novel SEC31A-anaplastic lymphoma kinase fusion in a patient with stage IV lung adenocarcinoma: a case report and literature reviews.
Wu R; Liu S; Lv G; Deng C; Wang R; Zhang S; Zhu D; Wang L; Lei Y; Luo Z
Anticancer Drugs; 2023 Feb; 34(2):294-301. PubMed ID: 36730620
[TBL] [Abstract][Full Text] [Related]
33. Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non-small cell lung cancer patients.
Lee PH; Chen KC; Hsu KH; Huang YH; Tseng JS; Yang TY; Chang GC
Anticancer Drugs; 2021 Nov; 32(10):1099-1104. PubMed ID: 34232936
[TBL] [Abstract][Full Text] [Related]
34. Lorlatinib for the treatment of inflammatory myofibroblastic tumour with TPM4-ALK fusion following failure of entrectinib.
Wong HH; Bentley H; Bulusu VR; Anyaegbu G; Watkins J; Horan G; Hatcher H
Anticancer Drugs; 2020 Nov; 31(10):1106-1110. PubMed ID: 32868646
[TBL] [Abstract][Full Text] [Related]
35. Pathological complete response to neoadjuvant lorlatinib in a patient with unresectable ALK-Positive locally advanced non-small cell lung cancer: A case report.
Chen R; Zhao L; Zhang J; Guo L; Chen Z; Pan X; Chen W
Heliyon; 2023 Nov; 9(11):e21582. PubMed ID: 38034719
[TBL] [Abstract][Full Text] [Related]
36. Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC.
Bokhari AA; Lai WY; Le AT; Gabre JL; Chuang TP; Fransson S; Bergman B; Djos A; Chen N; Martinsson T; Van den Eynden J; Doebele RC; Palmer RH; Hallberg B; Umapathy G
Lung Cancer; 2022 Sep; 171():103-114. PubMed ID: 35933914
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant immunotherapy plus chemotherapy and adjuvant targeted therapy in
Song Q; Li J; Xiong Q; Long YP; Yang B; Dong ZH; Liang CY; Yang B
Immunotherapy; 2023 Aug; 15(11):809-817. PubMed ID: 37254687
[TBL] [Abstract][Full Text] [Related]
38. Dynamic monitoring of circulating tumor DNA to analyze genetic characteristics and resistance profile of lorlatinib in ALK positive previously treated NSCLC.
Ma X; Zhang K; Xu J; Gao H; Yang S; Qin H; Wang H; Gao F; Liu X
Thorac Cancer; 2023 Jul; 14(20):1980-1990. PubMed ID: 37265111
[TBL] [Abstract][Full Text] [Related]
39. Lorlatinib for the treatment of patients with non-small cell lung cancer.
Akamine T; Toyokawa G; Tagawa T; Yamazaki K; Seto T; Takeo S; Mori M
Drugs Today (Barc); 2019 Feb; 55(2):107-116. PubMed ID: 30816885
[TBL] [Abstract][Full Text] [Related]
40. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]